Sera Prognostics Past Earnings Performance
Past criteria checks 0/6
Sera Prognostics's earnings have been declining at an average annual rate of -11.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 32.9% per year.
Key information
-11.7%
Earnings growth rate
69.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 32.9% |
| Return on equity | -59.0% |
| Net Margin | -34,302.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Not Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn
Jul 19
Sera Prognostics' PreTRM: A Speculative Buy In Women's Health
Mar 24Sera Prognostics: The Pregnancy Company On A Hot Streak
Jan 10Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?
Oct 03We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth
Jun 15We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate
Feb 16We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Nov 03A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening
Aug 10We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Jul 21Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation
Apr 06We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely
Dec 15Revenue & Expenses Breakdown
How Sera Prognostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -32 | 21 | 15 |
| 30 Jun 24 | 0 | -32 | 20 | 16 |
| 31 Mar 24 | 0 | -34 | 23 | 15 |
| 31 Dec 23 | 0 | -36 | 25 | 15 |
| 30 Sep 23 | 0 | -38 | 27 | 15 |
| 30 Jun 23 | 0 | -42 | 29 | 15 |
| 31 Mar 23 | 0 | -43 | 30 | 15 |
| 31 Dec 22 | 0 | -44 | 31 | 14 |
| 30 Sep 22 | 0 | -47 | 34 | 14 |
| 30 Jun 22 | 0 | -46 | 34 | 12 |
| 31 Mar 22 | 0 | -41 | 30 | 12 |
| 31 Dec 21 | 0 | -35 | 24 | 11 |
| 30 Sep 21 | 0 | -28 | 18 | 10 |
| 30 Jun 21 | 0 | -23 | 14 | 9 |
| 31 Mar 21 | 0 | -22 | 12 | 8 |
| 31 Dec 20 | 0 | -20 | 10 | 8 |
| 31 Dec 19 | 0 | -17 | 7 | 9 |
Quality Earnings: SERA is currently unprofitable.
Growing Profit Margin: SERA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SERA is unprofitable, and losses have increased over the past 5 years at a rate of 11.7% per year.
Accelerating Growth: Unable to compare SERA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SERA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SERA has a negative Return on Equity (-59%), as it is currently unprofitable.